Teenager’s Weight, Height May Increase Risk Of Developing Non-Hodgkin’s Lymphoma

Overweight teenagers and those taller than average compared to their peers could be at an increased risk of developing non-Hodgkin’s lymphoma (NHL), according to new research published in the journal Cancer.

The sixth most diagnosed cancer in the United States, researchers believe that rising obesity rates could explain this trend. Because they also wanted to see if being tall played a role in developing cancer, the researchers examined the association of NHL, body mass index and height by looking at the health records of two million-plus adolescents ages 16 to 19.

The results of the study revealed that overweight and obese teenagers were at a 25 percent higher risk for NHL compared to peers of a normal weight. When it came to height, shorter adolescents revealed a 25 percent decreased risk of NHL. The tallest people in the study showed a 28 percent increase in risk compared to peers considered to be of average height.

Inflammation

Researchers believe that height and poor nutritional habits during childhood influence inflammatory molecules and growth factors that may increase development of NHL.

“Obesity and overweight during adolescence are risk factors for future non-Hodgkin lymphoma,” said Dr. Merav Leiba, lead author of the study. “It is important to be aware that overweight and obesity are not risk factors only for diabetes and cardiovascular disease but also for lymphomas.”

The researchers stressed that additional studies are needed to further determine the reasons height and weight in teenagers appears to influence the risk of developing NHL.

Source: Lymphoma News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap